Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2025)

CG Oncology (CGON) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $849000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $849000.0, compared with a TTM value of $1.4 million through Dec 2025, up 4415.62%, and an annual FY2025 reading of $1.4 million, up 4415.62% over the prior year.
  • Depreciation & Amortization (CF) was $849000.0 for Q4 2025 at CG Oncology, up from $416000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $849000.0 in Q4 2025 and bottomed at $4000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $135818.2, with a median of $7000.0 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) changed 0.0% in 2024, then soared 2128.57% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $4000.0 in 2023, then skyrocketed by 425.0% to $21000.0 in 2024, then surged by 3942.86% to $849000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CGON at $849000.0 in Q4 2025, $416000.0 in Q3 2025, and $156000.0 in Q2 2025.